Company
Savara
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases.
Also known as Savara Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Legal name
- Savara Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Our lead product candidate, MOLBREEVI*, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).
Funding snapshot
- Total raised
- $30.9MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $26.8M2019-12-24
Funding rounds
- Round, 2019
- $26.8M2019-12-24, SEC form D sold, 18 investors
- Round, 2014
- $4.2M2014-02-27, SEC form D sold, 2 investors
Products
- Web
- MOLBREEVI
Loading relationship preview